Takeda shareholders fear dilution, debt from Shire deal pose ‘high risks,’ demand shareholders vote on it

Takeda shareholders fear dilution, debt from Shire deal pose ‘high risks,’ demand shareholders vote on it

Source: 
Fierce Pharma
snippet: 

Takeda’s long-sought $62 billion acquisition bid for Shire has launched the Japanese drugmaker into the big leagues, but it hasn’t quite been embraced by investors. The company’s shares have lost more than 20% of their value since late March, when Takeda was preparing its first of what ended up being five bids for Shire.